1. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. Issue 8 (10th March 2023) Authors: Vijenthira, Abi; Kuruvilla, John; Crump, Michael; Jain, Michael; Prica, Anca Journal: Journal of clinical oncology Issue: Volume 41:Issue 8(2023) Page Start: 1577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY. (9th November 2020) Authors: Mokhtari, Sepideh; Asquith, Justin; Bachmeier, Christina; Faramand, Rawan; Kim, Youngchul; Peguero, Edwin; Sahebjam, Solmaz; Jain, Michael; Vogelbaum, Michael; Davila, Marco; Forsyth, Peter; Locke, Frederick; Aleksandr, Lazaryan Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗